Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress

Craig S Anderson; Anthony Rodgers; H Asita De Silva; Sheila Ouriques Martins; Catharina Jm Klijn; Bimsara Senanayake; Ruth Freed; Laurent Billot; Hisatomi Arima; Nguyen Huy Thang; Wan Asyraf Wan Zaidi; Tinatin Kherkheulidze; Kolawole Wahab; Urs Fisher; Tsong-hai Lee; Christopher Chen; Octavio Pontes-neto; Thompson Robinson; Jiguang Wang; Sharon Naismith; Lili Song; Floris H Schreuder; Richard I Lindley; Mark Woodward; Stephen Macmahon; Rustam Al-shahi Salman; Clara K Chow; John Chalmers

doi:10.1177/17474930211068671

Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress

Craig S Anderson, Anthony Rodgers, H Asita De Silva, Sheila Ouriques Martins, Catharina Jm Klijn, Bimsara Senanayake, Ruth Freed, Laurent Billot, Hisatomi Arima, Nguyen Huy Thang, Wan Asyraf Wan Zaidi, Tinatin Kherkheulidze, Kolawole Wahab, Urs Fisher, Tsong-hai Lee, Christopher Chen, Octavio Pontes-neto, Thompson Robinson, Jiguang Wang, Sharon NaismithLili Song, Floris H Schreuder, Richard I Lindley, Mark Woodward, Stephen Macmahon, Rustam Al-shahi Salman, Clara K Chow, John Chalmers

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	174749302110686
Journal	International Journal of Stroke
DOIs	https://doi.org/10.1177/17474930211068671
Publication status	Published - 7 Jan 2022

Access to Document

10.1177/17474930211068671

Clean_TRIDENT protocol paper Version5_3December21
This is the author's peer-reviewed manuscript as accepted for publication.
Accepted author manuscript, 131 KB

http://journals.sagepub.com/doi/10.1177/17474930211068671

Cite this

Anderson, C. S., Rodgers, A., De Silva, H. A., Martins, S. O., Klijn, C. J., Senanayake, B., Freed, R., Billot, L., Arima, H., Thang, N. H., Zaidi, W. A. W., Kherkheulidze, T., Wahab, K., Fisher, U., Lee, T., Chen, C., Pontes-neto, O., Robinson, T., Wang, J., ... Chalmers, J. (2022). Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress. International Journal of Stroke, 174749302110686. https://doi.org/10.1177/17474930211068671

@article{eb1748582b304c9586376006853bb2ee,

title = "Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress",

author = "Anderson, {Craig S} and Anthony Rodgers and {De Silva}, {H Asita} and Martins, {Sheila Ouriques} and Klijn, {Catharina Jm} and Bimsara Senanayake and Ruth Freed and Laurent Billot and Hisatomi Arima and Thang, {Nguyen Huy} and Zaidi, {Wan Asyraf Wan} and Tinatin Kherkheulidze and Kolawole Wahab and Urs Fisher and Tsong-hai Lee and Christopher Chen and Octavio Pontes-neto and Thompson Robinson and Jiguang Wang and Sharon Naismith and Lili Song and Schreuder, {Floris H} and Lindley, {Richard I} and Mark Woodward and Stephen Macmahon and Salman, {Rustam Al-shahi} and Chow, {Clara K} and John Chalmers",

note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CSA holds a National Health and Medical Research Council (NHMRC) Investigator Fellowship and grants from Takeda, Penumbra, Genesis and Credit administered by his institution. AR is seconded part-time to GM, which is partly owned by GHE, the social enterprise arm of TGI, which holds patents for low-dose fixed-dose combination products for the treatment of hypertension and diabetes; AR is listed as one of the inventors (US 10,369,15; US 10,799,487; US 10,322,117; US 11,033,544). GHE and GM have received funding from public and private investors to conduct the research required for regulatory approval of cardiovascular combination products; AR does not have a financial interest in these patent applications or investments. SOM has received speaker fees from Boehringer Ingelheim, Medtronic, Bayer, Pfizer, Novartis, and Novo Nordisk. CJMK has received grant support from the Netherlands Cardiovascular Research Initiative, the Dutch Heart Foundation (CVON2015-01: CONTRAST), the Brain Foundation Netherlands (HA2015.01.06), Ministry of Economic Affairs for public-private partnerships (LSHM17016), and Stryker, Medtronic, and Cerenovus. TGR is a National Institute for Health Research (NIHR) Senior Investigator. MW is a consultant to Amgen, Freeline, and Kyowa Kirin. SM is a founder of GM and holds patents for low-dose triple combination antihypertensive formulations. CKC holds an NHMRC Investigator Fellowship. JC has received a grant from Idorsia for a study of resistant hypertension. All authors had full access to data for this study. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The National Health and Medical Research Council (NHMRC) of Australia (Grants 1149987 and 1103886) and PROADI SUS—Ministry of Health of Brazil and Hospital Moinhos de Vento (NUP number 25000.209767/2018-61). Publisher Copyright: {\textcopyright} 2022 World Stroke Organization.",

year = "2022",

month = jan,

day = "7",

doi = "10.1177/17474930211068671",

language = "English",

pages = "174749302110686",

journal = "International Journal of Stroke",

issn = "1747-4930",

publisher = "SAGE Publications",

}

Anderson, CS, Rodgers, A, De Silva, HA, Martins, SO, Klijn, CJ, Senanayake, B, Freed, R, Billot, L, Arima, H, Thang, NH, Zaidi, WAW, Kherkheulidze, T, Wahab, K, Fisher, U, Lee, T, Chen, C, Pontes-neto, O, Robinson, T, Wang, J, Naismith, S, Song, L, Schreuder, FH, Lindley, RI, Woodward, M, Macmahon, S, Salman, RA, Chow, CK & Chalmers, J 2022, 'Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress', International Journal of Stroke, pp. 174749302110686. https://doi.org/10.1177/17474930211068671

TY - JOUR

T1 - Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress

AU - Anderson, Craig S

AU - Rodgers, Anthony

AU - De Silva, H Asita

AU - Martins, Sheila Ouriques

AU - Klijn, Catharina Jm

AU - Senanayake, Bimsara

AU - Freed, Ruth

AU - Billot, Laurent

AU - Arima, Hisatomi

AU - Thang, Nguyen Huy

AU - Zaidi, Wan Asyraf Wan

AU - Kherkheulidze, Tinatin

AU - Wahab, Kolawole

AU - Fisher, Urs

AU - Lee, Tsong-hai

AU - Chen, Christopher

AU - Pontes-neto, Octavio

AU - Robinson, Thompson

AU - Wang, Jiguang

AU - Naismith, Sharon

AU - Song, Lili

AU - Schreuder, Floris H

AU - Lindley, Richard I

AU - Woodward, Mark

AU - Macmahon, Stephen

AU - Salman, Rustam Al-shahi

AU - Chow, Clara K

AU - Chalmers, John

N1 - Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CSA holds a National Health and Medical Research Council (NHMRC) Investigator Fellowship and grants from Takeda, Penumbra, Genesis and Credit administered by his institution. AR is seconded part-time to GM, which is partly owned by GHE, the social enterprise arm of TGI, which holds patents for low-dose fixed-dose combination products for the treatment of hypertension and diabetes; AR is listed as one of the inventors (US 10,369,15; US 10,799,487; US 10,322,117; US 11,033,544). GHE and GM have received funding from public and private investors to conduct the research required for regulatory approval of cardiovascular combination products; AR does not have a financial interest in these patent applications or investments. SOM has received speaker fees from Boehringer Ingelheim, Medtronic, Bayer, Pfizer, Novartis, and Novo Nordisk. CJMK has received grant support from the Netherlands Cardiovascular Research Initiative, the Dutch Heart Foundation (CVON2015-01: CONTRAST), the Brain Foundation Netherlands (HA2015.01.06), Ministry of Economic Affairs for public-private partnerships (LSHM17016), and Stryker, Medtronic, and Cerenovus. TGR is a National Institute for Health Research (NIHR) Senior Investigator. MW is a consultant to Amgen, Freeline, and Kyowa Kirin. SM is a founder of GM and holds patents for low-dose triple combination antihypertensive formulations. CKC holds an NHMRC Investigator Fellowship. JC has received a grant from Idorsia for a study of resistant hypertension. All authors had full access to data for this study. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The National Health and Medical Research Council (NHMRC) of Australia (Grants 1149987 and 1103886) and PROADI SUS—Ministry of Health of Brazil and Hospital Moinhos de Vento (NUP number 25000.209767/2018-61). Publisher Copyright: © 2022 World Stroke Organization.

PY - 2022/1/7

Y1 - 2022/1/7

U2 - 10.1177/17474930211068671

DO - 10.1177/17474930211068671

M3 - Article

SN - 1747-4930

SP - 174749302110686

JO - International Journal of Stroke

JF - International Journal of Stroke

ER -

Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress

Access to Document

Other files and links

Cite this